Discover the top 26 companies transforming the pharmaceutical drug delivery market, including Johnson & Johnson Services, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., and other industry leaders. Backed by a market projected to grow from $1,949.4M to $2,546.0M by 2029 at a CAGR of 5.5%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top Pharmaceutical Drug Delivery Companies

JOHNSON & JOHNSON SERVICES, INC.

Johnson & Johnson is a global healthcare leader specializing in innovative medicines and medical technologies. The company’s drug delivery expertise is integrated within its R&D engine, focusing on advanced modalities such as cell and gene therapies, RNA therapeutics, and diverse protein-based delivery systems. By leveraging multidisciplinary science and AI-driven discovery, Johnson & Johnson aims to address complex diseases in oncology, immunology, and neuroscience through transformational therapies and innovative manufacturing capabilities.

NOVARTIS AG

Novartis AG is a leading innovative medicines company dedicated to reimagining medicine through advanced technology platforms, including xRNA, radioligand therapy, and gene and cell therapy. The company emphasizes precision drug delivery to optimize treatment efficacy while minimizing damage to healthy tissue, particularly in oncology and cardiovascular health. With a robust global R&D network and a focus on high-value transformative treatments, Novartis continues to scale its delivery networks to enhance patient access and therapeutic outcomes worldwide.

F. HOFFMANN-LA ROCHE LTD.

F. Hoffmann-La Roche Ltd. is a pioneer in pharmaceuticals and diagnostics, focusing on high-burden diseases through cutting-edge research and early development. A key differentiator for Roche is its proprietary Brainshuttle technology, designed to enable the effective delivery of medicines across the blood-brain barrier for central nervous system disorders. By integrating AI and machine learning into its drug discovery process, Roche optimizes antibody design and small-molecule activity to deliver personalized healthcare solutions globally.

PFIZER INC.

Pfizer Inc. is a global biopharmaceutical giant recognized for its extensive capabilities in developing and delivering life-changing medicines and vaccines. In the drug delivery space, Pfizer leverages sophisticated technologies such as lipid nanoparticles (LNPs) and specialized formulations to ensure the stability and targeted release of biological therapies. The company’s commitment to innovation is supported by a massive manufacturing infrastructure and strategic collaborations aimed at addressing unmet medical needs in oncology, immunology, and rare diseases.

BECTON, DICKINSON AND COMPANY

Becton, Dickinson and Company (BD) is a global leader in medical technology, specifically focused on improving medical discovery, diagnostics, and the delivery of care. BD is a major player in the drug delivery market through its comprehensive portfolio of prefillable syringes, safety injection systems, and advanced infusion technologies. By collaborating with pharmaceutical companies to develop integrated delivery solutions, BD enhances patient safety and treatment adherence across both clinical and home care settings.

GLAXOSMITHKLINE PLC

GlaxoSmithKline PLC (GSK) is a global healthcare company focused on uniting science, technology, and talent to get ahead of disease together. GSK’s drug delivery strategy emphasizes the development of specialized inhaler technologies for respiratory conditions and advanced adjuvant systems for vaccines. Through its focus on infectious diseases and immunology, the company integrates innovative formulation science to improve the bioavailability and convenience of its therapeutic portfolio for patients worldwide.

MERCK & CO., INC.

Merck & Co., Inc. (known as MSD outside the U.S. and Canada) is a research-intensive biopharmaceutical company dedicated to delivering innovative health solutions. Merck utilizes advanced drug delivery technologies to support its industry-leading oncology franchise and extensive vaccine portfolio. The company focuses on enhancing the durability and precision of therapeutic delivery through long-acting formulations and specialized delivery devices, ensuring high-quality outcomes for patients managing chronic and infectious diseases.

SANOFI

Sanofi is an innovative global healthcare company driven by the purpose of chasing the miracles of science to improve people’s lives. In the realm of drug delivery, Sanofi specializes in advanced diabetes care through integrated insulin delivery systems and connected health solutions. Additionally, the company invests heavily in mRNA technology and specialized delivery platforms for immunology and rare diseases, focusing on patient-centric designs that simplify complex treatment regimens.

BAYER AG

Bayer AG is a global enterprise with core competencies in life science fields, particularly healthcare and nutrition. Its pharmaceutical division focuses on delivering innovative treatments in cardiology, oncology, and women’s health. Bayer utilizes sophisticated drug delivery platforms, including long-acting injectables and targeted delivery systems, to optimize the therapeutic index of its medications. The company’s commitment to digital health further supports its delivery strategy by enhancing patient monitoring and adherence.

AMGEN, INC.

Amgen, Inc. is one of the world’s leading biotechnology companies, specializing in the discovery and delivery of innovative human therapeutics for patients with serious illnesses. Amgen is at the forefront of drug delivery innovation with its development of user-friendly autoinjectors and on-body delivery systems that facilitate the administration of complex biologics. By focusing on biologics manufacturing and formulation science, Amgen ensures that its high-value therapies are delivered reliably and conveniently.

ABBVIE INC.

AbbVie Inc. is a global, research-driven biopharmaceutical company focused on developing advanced therapies for some of the world’s most complex and critical conditions. AbbVie’s drug delivery expertise is evident in its specialized formulations for immunology and oncology, including the use of targeted delivery technologies for its market-leading biologics. The company continues to invest in next-generation delivery systems, such as antibody-drug conjugates (ADCs) and sustained-release platforms, to improve clinical efficacy and patient experience.

GENMAB A/S

Genmab A/S is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics. Genmab’s contribution to drug delivery lies in its proprietary antibody technologies, such as DuoBody and HexaBody, which enable the design of multi-specific antibodies with precise targeting capabilities. These platforms allow for the delivery of potent therapeutic effects directly to disease-relevant cells, significantly advancing the standard of care in oncology and autoimmune diseases.

GILEAD SCIENCES, INC.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with a focus on HIV, viral hepatitis, and oncology. Gilead utilizes advanced formulation science to develop long-acting injectable therapies that reduce the burden of daily medication for patients with chronic viral infections. The company’s strategic focus on cell therapy and targeted delivery systems further enhances its ability to provide curative and life-extending treatments.

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Boehringer Ingelheim is a global, research-driven pharmaceutical company focused on human and animal health. A leader in respiratory medicine, the company is widely recognized for its innovative Respimat soft mist inhaler technology, which provides efficient and easy-to-use drug delivery for patients with COPD and asthma. Boehringer Ingelheim continues to expand its delivery capabilities into oncology and cardio-renal-metabolic diseases, emphasizing precision and sustainability in its device and formulation development.

ASTRAZENECA

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals. AstraZeneca is a leader in inhaled delivery technologies and is increasingly focusing on advanced delivery modalities such as lipid nanoparticles for genomic medicines. The company’s “Ambition Zero Carbon” initiative also drives innovation in sustainable drug delivery systems, aiming to reduce the environmental impact of its medical devices.

ELI LILLY AND COMPANY

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Lilly is a major innovator in the drug delivery market, particularly through its market-leading injectable platforms for diabetes and obesity care. The company’s focus on connected health and smart injection devices reflects its commitment to enhancing patient adherence and outcomes through intuitive, technology-enabled delivery solutions.

TEVA PHARMACEUTICAL INDUSTRIES LTD.

Teva Pharmaceutical Industries Ltd. is a global leader in generic and specialty medicines, providing essential treatments to millions of patients every day. Teva’s drug delivery portfolio includes a wide range of specialized respiratory products and injectable therapies, supported by its extensive manufacturing network. The company focuses on developing complex generic products that utilize sophisticated delivery mechanisms, such as transdermal patches and long-acting injectables, ensuring affordable access to advanced therapeutic delivery.

NOVO NORDISK A/S

Novo Nordisk A/S is a leading global healthcare company, founded in 1923 and headquartered in Denmark, with a primary focus on defeating diabetes and other serious chronic diseases. The company is a world leader in drug delivery innovation, particularly through its advanced insulin pens and the development of oral delivery platforms for GLP-1 therapies. Novo Nordisk continues to invest in smart injection devices and digital health integration to improve the precision and convenience of chronic disease management for patients worldwide.

GLENMARK PHARMACEUTICALS LTD.

Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a presence across generics, specialty, and OTC segments. Glenmark has established significant expertise in the drug delivery space through its focus on dermatology and respiratory therapies, utilizing specialized topical formulations and inhalation technologies. The company’s commitment to innovation is evidenced by its development of complex delivery systems that improve the bioavailability and patient compliance of its therapeutic offerings in emerging and developed markets.

VIATRIS INC

Viatris Inc. is a global healthcare company formed to provide high-quality medicines and sustainable healthcare solutions to patients regardless of geography or circumstance. Viatris maintains a diverse portfolio that includes complex generics and biosimilars, often utilizing advanced drug delivery technologies such as metered-dose inhalers and transdermal systems. By focusing on operational excellence and a broad commercial reach, Viatris ensures that sophisticated delivery options remain accessible and affordable for a wide patient population.

BRISTOL-MYERS SQUIBB COMPANY

Bristol-Myers Squibb (BMS) is a leading global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. BMS integrates advanced drug delivery strategies to support its expansive oncology, hematology, and immunology portfolios. The company focuses on optimizing the delivery of complex biologics and cell therapies, utilizing innovative formulation science and strategic collaborations to enhance the efficacy and safety profiles of its life-saving treatments.

SANDOZ GROUP AG

Sandoz Group AG is a global leader in generic and biosimilar medicines, specializing in providing high-quality, affordable healthcare solutions. In the drug delivery market, Sandoz offers a broad array of specialized dosage forms, including injectables, inhalants, and oral solids. The company is particularly recognized for its leadership in biosimilars, where it employs sophisticated analytical and manufacturing processes to ensure that its delivery systems meet the rigorous standards required for biologic therapies.

GERRESHEIMER AG

Gerresheimer AG is a leading global partner to the pharma and biotech industries, specializing in the design and manufacture of specialty glass and plastic drug delivery systems. Its extensive portfolio includes insulin pens, inhalers, prefillable syringes, and vials that are critical for the safe and effective administration of medicines. Gerresheimer focuses on sustainable and digitalized delivery solutions, partnering with pharmaceutical companies to develop integrated systems that improve patient safety and simplify the medication process.

BOSTON SCIENTIFIC CORPORATION

Boston Scientific Corporation is a global medical technology leader dedicated to transforming lives through innovative medical solutions. In the drug delivery market, the company is renowned for its drug-eluting stents and specialized catheter-based delivery systems used in interventional cardiology and peripheral vascular procedures. Boston Scientific’s expertise in site-specific delivery allows for the targeted release of medications to treat complex cardiovascular conditions, minimizing systemic side effects and improving long-term clinical outcomes.

CMP PHARMA

CMP Pharma is a specialized pharmaceutical company focused on developing and manufacturing high-quality liquid medications for niche markets where traditional dosage forms are inadequate. The company’s expertise lies in creating innovative liquid formulations and oral suspensions that provide accurate and convenient drug delivery for pediatric, geriatric, and other patient populations with swallowing difficulties. CMP Pharma’s focus on reformulating existing medications into patient-friendly delivery formats addresses significant unmet needs in clinical practice.

RUSAN PHARMA

Rusan Pharma is a research-driven pharmaceutical company specializing in the treatment of addiction, pain management, and tuberculosis. The company is a significant player in the drug delivery market through its development of advanced transdermal patches and long-acting injectables designed to improve patient compliance and therapeutic stability. Rusan Pharma’s vertically integrated capabilities allow it to innovate across the entire value chain, providing effective and reliable delivery solutions for critical public health challenges.

Download PDF Brochure:“Click Here”